We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENX:EURONEXT PARISEuronext NV Analysis

Data as of 2026-05-29 - not real-time

€139.80

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Euronext N.V. is currently trading at €139.8, which sits just below its 20‑day simple moving average of €142.5, hinting at modest short‑term pressure. The 50‑day SMA of €142.0 and the 200‑day SMA of €132.4 keep the medium‑term bias bullish, reinforced by the overall bullish trend direction. Momentum indicators are mixed: the RSI of 44 points to a neutral stance, while the MACD histogram remains negative, signaling bearish momentum in the near term. The stock finds technical support around €137.5 and faces resistance near €151.5, framing a relatively tight trading range. Despite the bearish MACD, the price‑to‑earnings multiple of roughly 21x exceeds the industry average of 16.5x, suggesting a premium valuation relative to peers. However, the discounted cash‑flow model places intrinsic value at €244, implying an upside potential of about 11% from current levels.
Fundamentals are solid, with revenue growth of 15% YoY, operating margins near 55% and free cash flow exceeding €1 bn, underpinning a robust balance sheet. The company generates €2.07 bn of cash and maintains a dividend yield of 2.27% with a payout ratio of 44%, indicating dividend sustainability. Debt stands at €3.41 bn but the debt‑to‑equity ratio of 69% remains manageable given strong cash generation. Recent commentary from CEO Stephane Boujnah ruled out an imminent merger with Deutsche Boerse, tempering expectations for a near‑term merger premium. The multi‑venue footprint across Europe and the United States provides geographic diversification that mitigates single‑market exposure. Taken together, the blend of attractive cash flow, a reasonable dividend and a sizable valuation gap supports a cautiously optimistic outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support level
  • bearish MACD histogram
  • neutral RSI reading

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF implied upside of ~11%
  • strong free cash flow generation
  • sustainable dividend yield

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • multi‑market European footprint
  • continued revenue growth
  • potential future M&A opportunities

Key Metrics & Analysis

Financial Health

Revenue Growth14.90%
Profit Margin35.53%
P/E Ratio21.3
ROE15.47%
ROA0.17%
Debt/Equity69.10
P/B Ratio3.0
Op. Cash Flow€1.1B
Free Cash Flow€1.1B
Industry P/E16.5

Technical Analysis

TrendBullish
RSI44.2
Support€137.50
Resistance€151.50
MA 20€142.47
MA 50€141.98
MA 200€132.36
MACDBearish
VolumeStable
Fear & Greed Index93.32

Valuation

Fair Value€244.42
Target Price€155.44
Upside/Downside11.19%
GradeUndervalued
TypeBlend
Dividend Yield2.27%

Risk Assessment

Beta-0.02
Volatility23.45%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.